Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Tumor-Agnostic 2Head & Neck 2CNS 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Classical hematology 1Breast 1

Conditions

Fanconi Anemia 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Epoetin Alfa 43Cyclosporine 43Busulfan 43Peripheral Blood Stem Cell Transplantation 39Mycophenolic Acid 34Darbepoetin alfa 33Antilymphocyte Serum 31Whole-Body Irradiation 30Cytarabine 30Filgrastim 29Methotrexate 26Tacrolimus 25Radiotherapy 25Melphalan 24fludarabine 21Methylprednisolone 17Cord Blood Stem Cell Transplantation 17Etoposide 14Granulocyte Colony-Stimulating Factor 13Daunorubicin 13Rivaroxaban 12apixaban 11Thiotepa 11sargramostim 10epoetin beta 10Dalteparin 10eltrombopag 9Alemtuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × prexasertib × Classical hematology × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡